These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 15842653

  • 1. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
    Harrison C.
    Br J Haematol; 2005 May; 129(3):293-306. PubMed ID: 15842653
    [Abstract] [Full Text] [Related]

  • 2. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y, Levine RL.
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [Abstract] [Full Text] [Related]

  • 3. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe.
    Griesshammer M, Struve S, Harrison CM.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):422-9. PubMed ID: 16810618
    [Abstract] [Full Text] [Related]

  • 4. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
    Gotoh A, Komatsu N.
    Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
    [No Abstract] [Full Text] [Related]

  • 5. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
    Johansson P, Kutti J, Andréasson B, Safai-Kutti S, Vilén L, Wedel H, Ridell B.
    J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
    [Abstract] [Full Text] [Related]

  • 6. The management of elderly patients with myeloproliferative disorders.
    Tura S.
    Hematol Oncol; 1993 Aug; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract] [Full Text] [Related]

  • 7. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A.
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [Abstract] [Full Text] [Related]

  • 8. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL.
    Clin Lab Sci; 2004 Nov; 17(4):223-34. PubMed ID: 15559729
    [Abstract] [Full Text] [Related]

  • 9. [The treatment of myeloproliferative syndromes].
    Maurice P.
    Schweiz Med Wochenschr; 1975 Oct 04; 105(40):1269-74. PubMed ID: 1061995
    [Abstract] [Full Text] [Related]

  • 10. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
    Griesshammer M, Struve S, Barbui T.
    Blood Rev; 2008 Sep 04; 22(5):235-45. PubMed ID: 18617299
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of myeloproliferative neoplasms].
    Motoji T.
    Rinsho Ketsueki; 2010 Oct 04; 51(10):1428-36. PubMed ID: 20962476
    [No Abstract] [Full Text] [Related]

  • 12. Myeloproliferative Neoplasms.
    Spivak JL.
    N Engl J Med; 2017 Jun 01; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of essential thrombocythemia during pregnancy with interferon-alpha.
    Delage R, Demers C, Cantin G, Roy J.
    Obstet Gynecol; 1996 May 01; 87(5 Pt 2):814-7. PubMed ID: 8677098
    [Abstract] [Full Text] [Related]

  • 14. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N.
    Br J Haematol; 2007 Mar 01; 136(5):745-51. PubMed ID: 17313377
    [Abstract] [Full Text] [Related]

  • 15. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
    Guglielmelli P, Bartalucci N, Rotunno G, Vannucchi AM.
    Expert Rev Hematol; 2014 Aug 01; 7(4):423-5. PubMed ID: 24849893
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
    Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, Hermine O.
    Respiration; 2008 Aug 01; 76(3):295-302. PubMed ID: 18160817
    [Abstract] [Full Text] [Related]

  • 17. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA, Pop VP, Seriakov AP.
    Vopr Onkol; 2004 Aug 01; 50(4):435-9. PubMed ID: 15605767
    [Abstract] [Full Text] [Related]

  • 18. A myeloproliferative disorder may hide another one.
    Laibe S, Tadrist Z, Arnoulet C, Sainty D, Mozziconacci MJ.
    Leuk Res; 2009 Aug 01; 33(8):1133-6. PubMed ID: 19250672
    [Abstract] [Full Text] [Related]

  • 19. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM, Thiele J.
    Pathobiology; 2007 Aug 01; 74(2):63-71. PubMed ID: 17587877
    [Abstract] [Full Text] [Related]

  • 20. Essential thrombocythemia and pregnancy.
    Valera MC, Parant O, Vayssiere C, Arnal JF, Payrastre B.
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct 01; 158(2):141-7. PubMed ID: 21640467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.